RT Journal Article
T1 Recombinant Peptide Mimetic NanoLuc Tracer for Sensitive Immunodetection of Mycophenolic Acid
A1 Luque Uria, Álvaro
A1 Peltomaa, Riikka Johanna
A1 Nevanen, Tarja K.
A1 Arola, Henri O.
A1 Iljin, Kristiina
A1 Benito Peña, María Elena
A1 Moreno Bondi, María Cruz
AB Mycophenolic acid (MPA) is an immunosuppressant drug commonly used to prevent organ rejection in transplanted patients. MPA monitoring is of great interest due to its small therapeutic window. In this work, a phage-displayed peptide library was used to select cyclic peptides that bind to the MPA-specific recombinant antibody fragment (Fab) and mimic the behavior of MPA. After biopanning, several phage-displayed peptides were isolated and tested to confirm their epitope-mimicking nature in phagebased competitive immunoassays. After identifying the best MPA mimetic (ACEGLYAHWC with a disulfide constrained loop), several immunoassay approaches were tested, and a recombinant fusion protein containing the peptide sequence with a bioluminescent enzyme, NanoLuc, was developed. The recombinant fusion enabled its direct use as the tracer in competitive immunoassays without the need for secondary antibodies or further labeling. A bioluminescent sensor, using streptavidin-coupled magnetic beads for the immobilization of the biotinylated Fab antibody, enabled the detection of MPA with a detection limit of 0.26 ng mL−1 and an IC50 of 2.9 ± 0.5 ng mL−1 . The biosensor showed good selectivity toward MPA and was applied to the analysis of the immunosuppressive drug in clinical samples, of both healthy and MPA-treated patients, followed by validation by liquid chromatography coupled to diode array detection
PB ACS Publications
SN 0003-2700
YR 2021
FD 2021-07-14
LK https://hdl.handle.net/20.500.14352/4596
UL https://hdl.handle.net/20.500.14352/4596
LA eng
NO CRUE-CSIC (Acuerdos Transformativos 2021)
DS Docta Complutense
RD 9 may 2025